← All trials
NCT05955885
Early Phase 1Interventional
Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies).
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2023
- Primary completion
- Jul 1, 2024
- Completion date
- Jul 1, 2024
- First posted
- Jul 21, 2023
- Last posted
- Jul 25, 2023
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MelbourneLead sponsor
- University of MelbourneOverall official - principal investigator
- University of MelbourneReponsible party - principal investigator
- Reckitt Benckiser PharmaceuticalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.